SUMMARY
- Structure Therapeutics sees over 30% share price jump with a promising obesity pill trial.
- Pill is a part of the GLP-1s class, mirroring gut hormones to suppress hunger.
- Global obesity drug market forecasted to reach $100 billion by the decade's end.
![broken image](http://custom-images.strikinglycdn.com/res/hrscywv4p/image/upload/c_limit,fl_lossy,h_9000,w_1200,f_auto,q_auto/9596329/141932_614457.jpeg)
In a rather exciting development, Structure Therapeutics' shares skyrocketed over 30% this Friday. The reason? Their new experimental pill designed to tackle obesity demonstrated promising results in a preliminary trial.
Participants, who were either overweight or obese, reported a significant weight loss of up to 10 pounds within a mere four-week period. Eager to further explore this promising venture, Structure is gearing up to put its innovative pill through two more rigorous trials, focusing on both obesity and diabetes treatments.
Structure's groundbreaking pill isn't exactly a newcomer in the pharmaceutical world. It belongs to the same drug class as Novo Nordisk's renowned diabetes treatment Ozempic and its sibling, the weight loss drug Wegovy. These drugs, identified as GLP-1s, have become the talk of the town this year, mainly for their remarkable efficacy in shedding those extra pounds. How do they work, you ask? Simply put, GLP-1s imitate a specific hormone in our guts, effectively curbing one's appetite.
And Structure isn't the only player in this game. The obesity drug arena is buzzing with activity, with experts predicting it could surge into a staggering $100 billion market globally before this decade bows out. Structure's pill might soon be locking horns with some potent contenders, specifically oral obesity drugs from pharmaceutical giants like Eli Lilly, Novo Nordisk, and Pfizer. These alternatives aren't U.S.-approved just yet, but they’re looming on the horizon. A rising trend is the tilt towards pills over injections, driven by their ease of manufacture and cost-effectiveness. The market might soon see cheaper, more accessible pill versions of GLP-1s, granting patients broader choices in obesity treatments.
Speaking of cost, the price tags on these treatments can raise eyebrows. For instance, Wegovy sets you back a cool $1,300 for a monthly package, while Ozempic comes in slightly cheaper at approximately $935. But here's a twist: Novo Nordisk's diabetes pill, Rybelsus, shares the same price point as Ozempic, yet offers a month-long supply of 30 tablets.
WOM Money Picks
Be a part of the winning team | 81% Success Rate.